Novo Nordisk Revenue vs. Price To Book
| NVO Stock | USD 105.06 2.43 2.37% |
Total Revenue | First Reported 1985-09-30 | Previous Quarter 68.1 B | Current Value 71.3 B | Quarterly Volatility 15.4 B |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.58 | 0.846 |
|
| |||||
| Net Profit Margin | 0.38 | 0.3603 |
|
| |||||
| Operating Profit Margin | 0.46 | 0.4416 |
|
| |||||
| Pretax Profit Margin | 0.47 | 0.4507 |
|
| |||||
| Return On Assets | 0.14 | 0.2661 |
|
| |||||
| Return On Equity | 0.82 | 0.7853 |
|
|
For Novo Nordisk profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Novo Nordisk to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Novo Nordisk AS utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Novo Nordisk's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Novo Nordisk AS over time as well as its relative position and ranking within its peers.
Novo |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novo Nordisk. If investors know Novo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novo Nordisk listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.224 | Dividend Share 9.9 | Earnings Share 2.99 | Revenue Per Share 60.698 | Quarterly Revenue Growth 0.214 |
The market value of Novo Nordisk AS is measured differently than its book value, which is the value of Novo that is recorded on the company's balance sheet. Investors also form their own opinion of Novo Nordisk's value that differs from its market value or its book value, called intrinsic value, which is Novo Nordisk's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novo Nordisk's market value can be influenced by many factors that don't directly affect Novo Nordisk's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novo Nordisk's value and its price as these two are different measures arrived at by different means. Investors typically determine if Novo Nordisk is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novo Nordisk's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Novo Nordisk AS Price To Book vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Novo Nordisk's current stock value. Our valuation model uses many indicators to compare Novo Nordisk value to that of its competitors to determine the firm's financial worth. Novo Nordisk AS is rated top company in revenue category among its peers. It is regarded fifth in price to book category among its peers . The ratio of Revenue to Price To Book for Novo Nordisk AS is about 8,677,853,001 . At this time, Novo Nordisk's Total Revenue is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novo Nordisk's earnings, one of the primary drivers of an investment's value.Novo Revenue vs. Competition
Novo Nordisk AS is rated top company in revenue category among its peers. Market size based on revenue of Health Care industry is now estimated at about 275.59 Billion. Novo Nordisk totals roughly 232.26 Billion in revenue claiming about 84% of equities under Health Care industry.
Novo Price To Book vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Novo Nordisk |
| = | 232.26 B |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Novo Nordisk |
| = | 26.76 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Novo Price To Book Comparison
Novo Nordisk is currently under evaluation in price to book category among its peers.
Novo Nordisk Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Novo Nordisk, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Novo Nordisk will eventually generate negative long term returns. The profitability progress is the general direction of Novo Nordisk's change in net profit over the period of time. It can combine multiple indicators of Novo Nordisk, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.3 B | 1.3 B | |
| Operating Income | 102.6 B | 107.7 B | |
| Income Before Tax | 104.7 B | 109.9 B | |
| Total Other Income Expense Net | 2.1 B | 2.2 B | |
| Net Income | 83.7 B | 87.9 B | |
| Income Tax Expense | 21 B | 22 B | |
| Net Income Applicable To Common Shares | 63.9 B | 67 B | |
| Net Income From Continuing Ops | 83.7 B | 87.9 B | |
| Interest Income | 1.1 B | 1.2 B | |
| Net Interest Income | 330 M | 346.5 M | |
| Change To Netincome | 25.5 B | 26.7 B | |
| Net Income Per Share | 18.67 | 19.60 | |
| Income Quality | 1.30 | 1.44 | |
| Net Income Per E B T | 0.80 | 0.58 |
Novo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Novo Nordisk. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Novo Nordisk position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Novo Nordisk's important profitability drivers and their relationship over time.
Use Novo Nordisk in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novo Nordisk position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novo Nordisk will appreciate offsetting losses from the drop in the long position's value.Novo Nordisk Pair Trading
Novo Nordisk AS Pair Trading Analysis
The ability to find closely correlated positions to Novo Nordisk could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novo Nordisk when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novo Nordisk - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novo Nordisk AS to buy it.
The correlation of Novo Nordisk is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novo Nordisk moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novo Nordisk AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Novo Nordisk can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Novo Nordisk position
In addition to having Novo Nordisk in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Toys Thematic Idea Now
Toys
Companies producing and distributing toys and different gaming products for kids. The Toys theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Toys Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
To fully project Novo Nordisk's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Novo Nordisk AS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Novo Nordisk's income statement, its balance sheet, and the statement of cash flows.